Data / Form D filings / Naegis Pharmaceuticals Inc.
Naegis Pharmaceuticals Inc.: Form D filing
Naegis Pharmaceuticals Inc., a company in Vancouver, British Columbia, Canada, filed a Form D with the SEC in 2024. The latest, on May 2, 2024, reports $350,812 sold of a $350,812 offering to 4 investors.
SpecStream is the live web data engine for teams and agents. It reads every Form D on SEC EDGAR the day it is filed, and this page is that reading. Ask for your own cut (a state, an industry, a size) and new filings arrive in your sheet, CRM, Slack or agent as they land.
Company details from the filing
- Address
- 999 WEST BROADWAY, SUITE 720, Vancouver, British Columbia, Canada, V5Z 1
- Phone
- (604) 235-1682
- Industry
- Other
- Entity type
- Corporation
- Incorporated in
- British Columbia, Canada
- Revenue range
- Decline to Disclose
- Exemptions claimed
- Rule 506(b)
- SEC identifier (CIK)
- 2021578
Form D filings
| Filed | Type | Offering | Sold | Remaining | Investors | First sale | Filing |
|---|---|---|---|---|---|---|---|
| May 2, 2024 | New notice | $350,812 | $350,812 | 4 | Apr 19, 2024 | sec.gov |
Executive officers and directors named in the filing
| Name | Role | Note in the filing |
|---|---|---|
| Philip Davies | Director | |
| Michael Liggett | Director | |
| Julian Gangolli | Director | |
| Cameron Groome | Director | |
| David Burgoyne | Executive Officer, Director | |
| Ian McBeath | Executive Officer, Director |
Every Form D from the week of Apr 29, 2024 · All recent Other filings
Read from SEC EDGAR. Amount sold is what Naegis Pharmaceuticals Inc. reported on the day it filed; on an offering that is still open, a later amendment can raise it. Free to reuse with credit to SpecStream under CC BY 4.0.